OBJECTIVES:  To quantify the effect of galantamine on burden of caregivers of patients with Alzheimer's Disease (AD) enrolled in INSPIRE (Investigation in a Naturalistic Setting of Patients Initiated on Reminyl).  METHODS:  INSPIRE is a prospective, observational study conducted across Canada in general practice and specialist sites, involving 471 patients 65 years or older with mild to moderate AD. Patient and caregiver demographics were recorded at baseline, with effectiveness measured by the Mini-Mental State Examination (MMSE) and Physician's Clinical Global Impression – Disease Status (CGI) at both baseline visit and final visit at 3 months. Caregiver stress was assessed using the Zarit Burden Interview (ZBI). Analysis was based on two-sided paired t-test.  RESULTS:  This preliminary analysis included 248 patients and caregivers, all of whom had completed the study at time of analysis. Of these patients, the mean age was 80.6 ± 6.5, 61% were female, 54% had a high school degree or less, and 74% lived with their spouse or partner. The mean age of caregivers was 61.4 ± 14.6. The caregiver sample was predominately female (75%), most lived with the patient (54%), and 42% employed on a full-time or part-time basis. At baseline, the mean caregiver ZBI score was 21.5 ± 12.6. Significant improvement in caregiver burden (mean change 1.5 ± 8.4, p=0.006) was shown after three months of galantamine treatment.  CONCLUSIONS: The efficacy and safety of galantamine has been demonstrated in multiple randomized, double-blind, placebo-controlled trials in patients with mild-to-moderate AD.  This naturalistic study shows that galantamine significantly reduces burden among caregivers of patients with AD. Overall, galantamine has a broad ranging beneficial effect from both patient and caregiver perspectives.